APO Research
Talk to an analyst

APO RESEARCH · REPORT

Afatinib Dimaleate

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Afatinib Dimaleate Industry Growth and Trends Forecast to 2032

2 January 2026106 pages

Choose your research edition.

Industry ResearchAfatinib Dimaleate Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Afatinib Dimaleate Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Afatinib Dimaleate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Afatinib Dimaleate Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Afatinib Dimaleate Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Afatinib Dimaleate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Afatinib Dimaleate include Boehringer-Ingelheim, Beacon Pharmaceuticals, Hansoh Pharmaceuticak, Kelun－Kazpharm, Merck, Qilu Pharmaceutical, Qingfeng Medicine Group, CSPC Pharmaceutical and Yangtze River Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Afatinib Dimaleate market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Afatinib Dimaleate market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Afatinib Dimaleate market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Afatinib Dimaleate.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Afatinib Dimaleate market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Afatinib Dimaleate Market by Company

Boehringer-Ingelheim

Beacon Pharmaceuticals

Hansoh Pharmaceuticak

Kelun－Kazpharm

Merck

Qilu Pharmaceutical

Qingfeng Medicine Group

CSPC Pharmaceutical

Yangtze River Pharm

Chia Tai-Tianqing

Afatinib Dimaleate Segment by Type

20 mg

30 mg

40 mg

Afatinib Dimaleate Segment by Application

Hospital

Clinic

Afatinib Dimaleate Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib Dimaleate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Afatinib Dimaleate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib Dimaleate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Afatinib Dimaleate manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Afatinib Dimaleate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 20 mg Table 2. Major Company of 30 mg Table 3. Major Company of 40 mg Table 4. Global Afatinib Dimaleate Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 6. Global Afatinib Dimaleate Sales Market Share in Volume by Type (2021-2026) Table 7. Global Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 8. Global Afatinib Dimaleate Sales Market Share in Value by Type (2021-2026) Table 9. Global Afatinib Dimaleate Price by Type (2021-2026) & (US$/Unit) Table 10. Global Afatinib Dimaleate Sales by Type (2027-2032) & (K Units) Table 11. Global Afatinib Dimaleate Sales Market Share in Volume by Type (2027-2032) Table 12. Global Afatinib Dimaleate Sales by Type (2027-2032) & (US$ Million) Table 13. Global Afatinib Dimaleate Sales Market Share in Value by Type (2027-2032) Table 14. Global Afatinib Dimaleate Price by Type (2027-2032) & (US$/Unit) Table 15. North America Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 16. North America Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 18. Europe Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 22. Latin America Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Afatinib Dimaleate Sales by Type (2021-2026) & (US$ Million) Table 25. Afatinib Dimaleate Industry Trends Table 26. Afatinib Dimaleate Industry Drivers Table 27. Afatinib Dimaleate Industry Opportunities and Challenges Table 28. Afatinib Dimaleate Industry Restraints Table 29. Global Afatinib Dimaleate Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Afatinib Dimaleate Revenue Market Share by Company (2021-2026) Table 31. Global Afatinib Dimaleate Sales by Company (2021-2026) & (K Units) Table 32. Global Afatinib Dimaleate Sales Share by Company (2021-2026) Table 33. Global Afatinib Dimaleate Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Afatinib Dimaleate Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Afatinib Dimaleate Major Company Production Sites and Headquarters Table 36. Global Afatinib Dimaleate Company, Product Type & Application Table 37. Global Afatinib Dimaleate Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Afatinib Dimaleate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Afatinib Dimaleate Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Afatinib Dimaleate Sales by Region (2021-2026) & (K Units) Table 42. Global Afatinib Dimaleate Sales Market Share in Volume by Region (2021-2026) Table 43. Global Afatinib Dimaleate Sales by Region (2021-2026) & (US$ Million) Table 44. Global Afatinib Dimaleate Sales Market Share in Value by Region (2021-2026) Table 45. Global Afatinib Dimaleate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Afatinib Dimaleate Sales by Region (2027-2032) & (K Units) Table 47. Global Afatinib Dimaleate Sales Market Share in Volume by Region (2027-2032) Table 48. Global Afatinib Dimaleate Sales by Region (2027-2032) & (US$ Million) Table 49. Global Afatinib Dimaleate Sales Market Share in Value by Region (2027-2032) Table 50. Global Afatinib Dimaleate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Afatinib Dimaleate Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 53. Global Afatinib Dimaleate Sales Market Share in Volume by Application (2021-2026) Table 54. Global Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 55. Global Afatinib Dimaleate Sales Market Share in Value by Application (2021-2026) Table 56. Global Afatinib Dimaleate Price by Application (2021-2026) & (US$/Unit) Table 57. Global Afatinib Dimaleate Sales by Application (2027-2032) & (K Units) Table 58. Global Afatinib Dimaleate Sales Market Share in Volume by Application (2027-2032) Table 59. Global Afatinib Dimaleate Sales by Application (2027-2032) & (US$ Million) Table 60. Global Afatinib Dimaleate Sales Market Share in Value by Application (2027-2032) Table 61. Global Afatinib Dimaleate Price by Application (2027-2032) & (US$/Unit) Table 62. North America Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 63. North America Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 65. Europe Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 69. Latin America Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Afatinib Dimaleate Sales by Application (2021-2026) & (US$ Million) Table 72. Boehringer-Ingelheim Company Information Table 73. Boehringer-Ingelheim Business Overview Table 74. Boehringer-Ingelheim Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio Table 76. Boehringer-Ingelheim Recent Development Table 77. Beacon Pharmaceuticals Company Information Table 78. Beacon Pharmaceuticals Business Overview Table 79. Beacon Pharmaceuticals Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio Table 81. Beacon Pharmaceuticals Recent Development Table 82. Hansoh Pharmaceuticak Company Information Table 83. Hansoh Pharmaceuticak Business Overview Table 84. Hansoh Pharmaceuticak Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio Table 86. Hansoh Pharmaceuticak Recent Development Table 87. Kelun－Kazpharm Company Information Table 88. Kelun－Kazpharm Business Overview Table 89. Kelun－Kazpharm Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Kelun－Kazpharm Afatinib Dimaleate Product Portfolio Table 91. Kelun－Kazpharm Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merck Afatinib Dimaleate Product Portfolio Table 96. Merck Recent Development Table 97. Qilu Pharmaceutical Company Information Table 98. Qilu Pharmaceutical Business Overview Table 99. Qilu Pharmaceutical Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio Table 101. Qilu Pharmaceutical Recent Development Table 102. Qingfeng Medicine Group Company Information Table 103. Qingfeng Medicine Group Business Overview Table 104. Qingfeng Medicine Group Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio Table 106. Qingfeng Medicine Group Recent Development Table 107. CSPC Pharmaceutical Company Information Table 108. CSPC Pharmaceutical Business Overview Table 109. CSPC Pharmaceutical Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio Table 111. CSPC Pharmaceutical Recent Development Table 112. Yangtze River Pharm Company Information Table 113. Yangtze River Pharm Business Overview Table 114. Yangtze River Pharm Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Yangtze River Pharm Afatinib Dimaleate Product Portfolio Table 116. Yangtze River Pharm Recent Development Table 117. Chia Tai-Tianqing Company Information Table 118. Chia Tai-Tianqing Business Overview Table 119. Chia Tai-Tianqing Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio Table 121. Chia Tai-Tianqing Recent Development Table 122. North America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. North America Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 124. North America Afatinib Dimaleate Sales Market Share by Country (2021-2026) Table 125. North America Afatinib Dimaleate Sales Forecast by Country (2027-2032) & (K Units) Table 126. North America Afatinib Dimaleate Sales Market Share Forecast by Country (2027-2032) Table 127. North America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America Afatinib Dimaleate Market Size by Country (2021-2026) & (US$ Million) Table 129. North America Afatinib Dimaleate Market Share by Country (2021-2026) Table 130. North America Afatinib Dimaleate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America Afatinib Dimaleate Market Share Forecast by Country (2027-2032) Table 132. Europe Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Europe Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 134. Europe Afatinib Dimaleate Sales Market Share by Country (2021-2026) Table 135. Europe Afatinib Dimaleate Sales Forecast by Country (2027-2032) & (K Units) Table 136. Europe Afatinib Dimaleate Sales Market Share Forecast by Country (2027-2032) Table 137. Europe Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe Afatinib Dimaleate Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe Afatinib Dimaleate Market Share by Country (2021-2026) Table 140. Europe Afatinib Dimaleate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe Afatinib Dimaleate Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 144. Asia-Pacific Afatinib Dimaleate Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific Afatinib Dimaleate Sales Forecast by Country (2027-2032) & (K Units) Table 146. Asia-Pacific Afatinib Dimaleate Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Afatinib Dimaleate Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific Afatinib Dimaleate Market Share by Country (2021-2026) Table 150. Asia-Pacific Afatinib Dimaleate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific Afatinib Dimaleate Market Share Forecast by Country (2027-2032) Table 152. Latin America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. Latin America Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 154. Latin America Afatinib Dimaleate Sales Market Share by Country (2021-2026) Table 155. Latin America Afatinib Dimaleate Sales Forecast by Country (2027-2032) & (K Units) Table 156. Latin America Afatinib Dimaleate Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America Afatinib Dimaleate Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America Afatinib Dimaleate Market Share by Country (2021-2026) Table 160. Latin America Afatinib Dimaleate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America Afatinib Dimaleate Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 164. Middle East and Africa Afatinib Dimaleate Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa Afatinib Dimaleate Sales Forecast by Country (2027-2032) & (K Units) Table 166. Middle East and Africa Afatinib Dimaleate Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Afatinib Dimaleate Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa Afatinib Dimaleate Market Share by Country (2021-2026) Table 170. Middle East and Africa Afatinib Dimaleate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa Afatinib Dimaleate Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Afatinib Dimaleate Distributors List Table 175. Afatinib Dimaleate Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Afatinib Dimaleate Image Figure 2. Global Afatinib Dimaleate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Afatinib Dimaleate Market Size (2021-2032) & (US$ Million) Figure 4. Global Afatinib Dimaleate Sales (2021-2032) & (K Units) Figure 5. 20 mg Image Figure 6. Global 20 mg Sales YoY Growth (2021-2032) & (K Units) Figure 7. 30 mg Image Figure 8. Global 30 mg Sales YoY Growth (2021-2032) & (K Units) Figure 9. 40 mg Image Figure 10. Global 40 mg Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Afatinib Dimaleate Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Afatinib Dimaleate Market Share by Type 2025 VS 2032 Figure 13. North America Afatinib Dimaleate Sales Market Share in Volume by Type in 2025 Figure 14. North America Afatinib Dimaleate Sales Market Share in Value by Type in 2025 Figure 15. Europe Afatinib Dimaleate Sales Market Share in Volume by Type in 2025 Figure 16. Europe Afatinib Dimaleate Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Afatinib Dimaleate Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Afatinib Dimaleate Sales Market Share in Value by Type in 2025 Figure 19. Latin America Afatinib Dimaleate Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Afatinib Dimaleate Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Afatinib Dimaleate Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Afatinib Dimaleate Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Afatinib Dimaleate Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Afatinib Dimaleate Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Afatinib Dimaleate Market Share by Application 2025 VS 2032 Figure 31. North America Afatinib Dimaleate Sales Market Share in Volume by Application in 2025 Figure 32. North America Afatinib Dimaleate Sales Market Share in Value by Application in 2025 Figure 33. Europe Afatinib Dimaleate Sales Market Share in Volume by Application in 2025 Figure 34. Europe Afatinib Dimaleate Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Afatinib Dimaleate Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Afatinib Dimaleate Sales Market Share in Value by Application in 2025 Figure 37. Latin America Afatinib Dimaleate Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Afatinib Dimaleate Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Afatinib Dimaleate Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Afatinib Dimaleate Sales Market Share in Value by Application in 2025 Figure 41. North America Afatinib Dimaleate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Afatinib Dimaleate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Afatinib Dimaleate Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Afatinib Dimaleate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Afatinib Dimaleate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Afatinib Dimaleate Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Afatinib Dimaleate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Afatinib Dimaleate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Afatinib Dimaleate Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Afatinib Dimaleate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Afatinib Dimaleate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Afatinib Dimaleate Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Afatinib Dimaleate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Afatinib Dimaleate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Afatinib Dimaleate Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Afatinib Dimaleate Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Afatinib Dimaleate Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 20 mg
  • 30 mg
  • 40 mg
Applications
  • Hospital
  • Clinic
Companies covered
  • Boehringer-Ingelheim
  • Beacon Pharmaceuticals
  • Hansoh Pharmaceuticak
  • Kelun－Kazpharm
  • Merck
  • Qilu Pharmaceutical
  • Qingfeng Medicine Group
  • CSPC Pharmaceutical
  • Yangtze River Pharm
  • Chia Tai-Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Afatinib Dimaleate Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Afatinib Dimaleate Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Afatinib Dimaleate Market by Type
  6. 1.3.1 20 mg
  7. 1.3.2 30 mg
  8. 1.3.3 40 mg
  9. 1.4 Global Afatinib Dimaleate Market Size by Type
  10. 1.4.1 Global Afatinib Dimaleate Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Afatinib Dimaleate Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Afatinib Dimaleate Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Afatinib Dimaleate Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Afatinib Dimaleate Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Afatinib Dimaleate Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Afatinib Dimaleate Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Afatinib Dimaleate Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Afatinib Dimaleate Industry Trends
  2. 2.2 Afatinib Dimaleate Industry Drivers
  3. 2.3 Afatinib Dimaleate Industry Opportunities and Challenges
  4. 2.4 Afatinib Dimaleate Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Afatinib Dimaleate Revenue (2021-2026)
  2. 3.2 Global Top Players by Afatinib Dimaleate Sales (2021-2026)
  3. 3.3 Global Top Players by Afatinib Dimaleate Price (2021-2026)
  4. 3.4 Global Afatinib Dimaleate Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Afatinib Dimaleate Major Company Production Sites & Headquarters
  6. 3.6 Global Afatinib Dimaleate Company, Product Type & Application
  7. 3.7 Global Afatinib Dimaleate Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Afatinib Dimaleate Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Afatinib Dimaleate Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Afatinib Dimaleate Tier 1, Tier 2, and Tier 3
4 Afatinib Dimaleate Regional Status and Outlook
  1. 4.1 Global Afatinib Dimaleate Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Afatinib Dimaleate Historic Market Size by Region
  3. 4.2.1 Global Afatinib Dimaleate Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Afatinib Dimaleate Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Afatinib Dimaleate Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Afatinib Dimaleate Forecasted Market Size by Region
  7. 4.3.1 Global Afatinib Dimaleate Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Afatinib Dimaleate Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Afatinib Dimaleate Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Afatinib Dimaleate by Application
  1. 5.1 Afatinib Dimaleate Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Afatinib Dimaleate Market Size by Application
  5. 5.2.1 Global Afatinib Dimaleate Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Afatinib Dimaleate Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Afatinib Dimaleate Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Afatinib Dimaleate Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Afatinib Dimaleate Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Afatinib Dimaleate Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Afatinib Dimaleate Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Afatinib Dimaleate Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Boehringer-Ingelheim
  2. 6.1.1 Boehringer-Ingelheim Company Information
  3. 6.1.2 Boehringer-Ingelheim Business Overview
  4. 6.1.3 Boehringer-Ingelheim Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio
  6. 6.1.5 Boehringer-Ingelheim Recent Developments
  7. 6.2 Beacon Pharmaceuticals
  8. 6.2.1 Beacon Pharmaceuticals Company Information
  9. 6.2.2 Beacon Pharmaceuticals Business Overview
  10. 6.2.3 Beacon Pharmaceuticals Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio
  12. 6.2.5 Beacon Pharmaceuticals Recent Developments
  13. 6.3 Hansoh Pharmaceuticak
  14. 6.3.1 Hansoh Pharmaceuticak Company Information
  15. 6.3.2 Hansoh Pharmaceuticak Business Overview
  16. 6.3.3 Hansoh Pharmaceuticak Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio
  18. 6.3.5 Hansoh Pharmaceuticak Recent Developments
  19. 6.4 Kelun－Kazpharm
  20. 6.4.1 Kelun－Kazpharm Company Information
  21. 6.4.2 Kelun－Kazpharm Business Overview
  22. 6.4.3 Kelun－Kazpharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Kelun－Kazpharm Afatinib Dimaleate Product Portfolio
  24. 6.4.5 Kelun－Kazpharm Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Afatinib Dimaleate Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Qilu Pharmaceutical
  32. 6.6.1 Qilu Pharmaceutical Company Information
  33. 6.6.2 Qilu Pharmaceutical Business Overview
  34. 6.6.3 Qilu Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio
  36. 6.6.5 Qilu Pharmaceutical Recent Developments
  37. 6.7 Qingfeng Medicine Group
  38. 6.7.1 Qingfeng Medicine Group Company Information
  39. 6.7.2 Qingfeng Medicine Group Business Overview
  40. 6.7.3 Qingfeng Medicine Group Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio
  42. 6.7.5 Qingfeng Medicine Group Recent Developments
  43. 6.8 CSPC Pharmaceutical
  44. 6.8.1 CSPC Pharmaceutical Company Information
  45. 6.8.2 CSPC Pharmaceutical Business Overview
  46. 6.8.3 CSPC Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio
  48. 6.8.5 CSPC Pharmaceutical Recent Developments
  49. 6.9 Yangtze River Pharm
  50. 6.9.1 Yangtze River Pharm Company Information
  51. 6.9.2 Yangtze River Pharm Business Overview
  52. 6.9.3 Yangtze River Pharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Yangtze River Pharm Afatinib Dimaleate Product Portfolio
  54. 6.9.5 Yangtze River Pharm Recent Developments
  55. 6.10 Chia Tai-Tianqing
  56. 6.10.1 Chia Tai-Tianqing Company Information
  57. 6.10.2 Chia Tai-Tianqing Business Overview
  58. 6.10.3 Chia Tai-Tianqing Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio
  60. 6.10.5 Chia Tai-Tianqing Recent Developments
7 North America by Country
  1. 7.1 North America Afatinib Dimaleate Sales by Country
  2. 7.1.1 North America Afatinib Dimaleate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Afatinib Dimaleate Sales by Country (2021-2026)
  4. 7.1.3 North America Afatinib Dimaleate Sales Forecast by Country (2027-2032)
  5. 7.2 North America Afatinib Dimaleate Market Size by Country
  6. 7.2.1 North America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Afatinib Dimaleate Market Size by Country (2021-2026)
  8. 7.2.3 North America Afatinib Dimaleate Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Afatinib Dimaleate Sales by Country
  2. 8.1.1 Europe Afatinib Dimaleate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Afatinib Dimaleate Sales by Country (2021-2026)
  4. 8.1.3 Europe Afatinib Dimaleate Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Afatinib Dimaleate Market Size by Country
  6. 8.2.1 Europe Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Afatinib Dimaleate Market Size by Country (2021-2026)
  8. 8.2.3 Europe Afatinib Dimaleate Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Afatinib Dimaleate Sales by Country
  2. 9.1.1 Asia-Pacific Afatinib Dimaleate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Afatinib Dimaleate Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Afatinib Dimaleate Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Afatinib Dimaleate Market Size by Country
  6. 9.2.1 Asia-Pacific Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Afatinib Dimaleate Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Afatinib Dimaleate Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Afatinib Dimaleate Sales by Country
  2. 10.1.1 South America Afatinib Dimaleate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Afatinib Dimaleate Sales by Country (2021-2026)
  4. 10.1.3 South America Afatinib Dimaleate Sales Forecast by Country (2027-2032)
  5. 10.2 South America Afatinib Dimaleate Market Size by Country
  6. 10.2.1 South America Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Afatinib Dimaleate Market Size by Country (2021-2026)
  8. 10.2.3 South America Afatinib Dimaleate Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Afatinib Dimaleate Sales by Country
  2. 11.1.1 Middle East and Africa Afatinib Dimaleate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Afatinib Dimaleate Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Afatinib Dimaleate Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Afatinib Dimaleate Market Size by Country
  6. 11.2.1 Middle East and Africa Afatinib Dimaleate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Afatinib Dimaleate Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Afatinib Dimaleate Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Afatinib Dimaleate Value Chain Analysis
  2. 12.1.1 Afatinib Dimaleate Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Afatinib Dimaleate Production Mode & Process
  7. 12.2 Afatinib Dimaleate Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Afatinib Dimaleate Distributors
  10. 12.2.3 Afatinib Dimaleate Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst